San Diego, Calif.-based Cell Applications said the launch will allow them to offer pay-for-service bio-printing to make scaffold-free tissue available for research use.
“In addition to customized cell isolation and assay services, Cell Applications is now able to provide researchers with an integrated cell-engineering solution that utilizes our expansive primary cell bank and the innovative Kenzan bioprinting method. the Regenova 3D Bio Printer at our San Diego headquarters with our vast array of primary cells is a powerful combination. We’re very pleased to offer researchers an end-to-end, customized solution for creating scaffold-free, 3D-engineered tissues that reduce costs by minimizing the lengthy processes typical in pharmaceutical drug discovery,” Cell Applications CEO James Yu said in prepared remarks.
The Regenova system does not require biomaterial scaffolding made from collagen or hydrogel, the companies said, as the device assembles macroscopic tissue by forming cell aggregates, called spheroids, by lancing them onto a fine needle array.
“The Regenova 3D Bio Printer, combined with Cell Applications’ comprehensive, high-quality primary cell bank, offers researchers streamlined access to a nearly limitless selection of three dimensional tissues including those mimicking blood vessels, human neural tissue and liver constructs. The collective strengths of both our companies will serve the growing demand for viable engineered tissues and accelerate scientific discovery in North America, taking us one step closer to making regenerative medicine a reality,” Cyfuse Biomedical CEO Koji Kuchiishi said in a press release.